ExodusPoint Capital Management’s Ovid Therapeutics OVID Stock Holding History

ExodusPoint Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,392	Closed	-$25K	–	2037
2022 Q4	$25K	Buy	+13,392	New	+$22.8K	﹤0.01%	1564
2021 Q4	–	Sell	-19,491	Closed	-$65K	–	2487
2021 Q3	$65K	Sell	19,491 -34,444	-64%	-$126K	﹤0.01%	1955
2021 Q2	$211K	Buy	+53,935	New	+$213K	﹤0.01%	1956
2020 Q4	–	Sell	-14,561	Closed	-$84K	–	2277
2020 Q3	$84K	Buy	+14,561	New	+$97.4K	﹤0.01%	1610
2020 Q2	–	Sell	-50,557	Closed	-$151K	–	1955
2020 Q1	$151K	Sell	50,557 -97,183	-66%	-$327K	0.01%	837
2019 Q4	$613K	Buy	+147,740	New	+$467K	0.01%	759

Other funds holding OVID

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

ExodusPoint Capital Management's OVID Position: Q1 2023 in Review

ExodusPoint Capital Management sold out of Ovid Therapeutics (OVID) in Q1 2023, closing a stake of 13,392 shares — an estimated $25K sold.

ExodusPoint Capital Management first reported a position in OVID in Q4 2019 and held it in 6 quarters. The position peaked at $613K in Q4 2019. 60 funds tracked by Wall St. Rank hold OVID as of Q1 2023.

ExodusPoint Capital Management reported no remaining Ovid Therapeutics position as of Q1 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 13,392 Ovid Therapeutics shares in Q1 2023, an estimated $25K.
ExodusPoint Capital Management first reported a position in Ovid Therapeutics in Q4 2019 and held it in 6 quarters.
ExodusPoint Capital Management's Ovid Therapeutics position peaked at $613K in Q4 2019.
60 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.